We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Some Accelerated Approval Cancer Drugs Remain Recommended Despite Failed Postmarket Trials
Some Accelerated Approval Cancer Drugs Remain Recommended Despite Failed Postmarket Trials
A third of the indications for cancer drugs that failed their confirmatory trials after accelerated approval remain on the label for years, with some even getting high endorsements from an alliance of 31 leading oncology centers.